Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Pre-clinical and human neuropharmacological evidence suggests a role of cholinergic modulation of monoamines as a pathophysiological and therapeutic mechanism in Alzheimer's disease. The present study measured the effects of treatment with the cholinesterase inhibitor and nicotinic receptor modulator, galantamine, on the cerebral metabolic response to the selective serotonin reuptake inhibitor, citalopram. Seven probable Alzheimer's disease patients and seven demographically comparable controls underwent two positron emission tomography (PET) glucose metabolism scans, after administration of a saline placebo infusion (Day 1) and after citalopram (40 mg, IV, Day 2). The scan protocol was repeated in the Alzheimer's disease patients 2 months after titration to a 24 mg galantamine dose. At baseline, cerebral glucose metabolism was reduced in Alzheimer's disease patients relative to controls in right middle temporal, left posterior cingulate and parietal cortices (precuneus and inferior parietal lobule), as expected. Both groups demonstrated acute decreases in cerebral glucose metabolism after citalopram to a greater extent in the Alzheimer's disease patients. In the patients, relative to the controls, citalopram decreased glucose metabolism to a greater extent in middle frontal gyrus (bilaterally), left middle temporal gyrus and right posterior cingulate prior to treatment. Galantamine treatment alone increased metabolism in the right precuneus, right inferior parietal lobule and right middle occipital gyrus. In contrast, during galantamine treatment, citalopram increased metabolism in the right middle frontal gyrus, right post-central gyrus, right superior and middle temporal gyrus and right cerebellum. The combined cerebral metabolic effects of galantamine and citalopram suggest, consistent with preclinical data, a synergistic interaction of cholinergic and serotonergic systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802 · cited 3×
“…in right middle temporal, left posterior cingulate and parietal cortices (precuneus and inferior parietal lobule), consistent with the pattern of metabolic deficits in Alzheimer's disease shown in prior studies using voxel-based data analysis methods (Minoshima et al., 1997: Reiman et al., 2005 ).”
Mazoyer, B., Zago, L., Mellet, E., Bricogne, S., Etard, O., Houdé, O., Crivello, F., Joliot, M., Petit, L., & Tzourio-Mazoyer, N. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00437-8 · Cited by 906
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
The mind's eye – precuneus activation in memory-related imagery
Fletcher, P. C., Frith, C. D., Baker, S. C., Shallice, T., Frackowiak, R. S. J., & Dolan, R. J. (1995) · NeuroImage · doi:10.1006/nimg.1995.1025 · Cited by 680 · cited 1×
“…effects of acute citalopram and the pattern observed with behavioural activation paradigms, including mood induction, attention and memory tasks and during conditions of hunger and satiety (as reviewed in Fletcher et al., 1995; Tataranni et al., 1999: Liotti et al., 2000; Smith et al., 2002a, b).”
Liotti, M., Mayberg, H. S., Brannan, S. K., McGinnis, S., Jerabek, P., & Fox, P. T. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00874-x · Cited by 424 · cited 1×
“…effects of acute citalopram and the pattern observed with behavioural activation paradigms, including mood induction, attention and memory tasks and during conditions of hunger and satiety (as reviewed in Fletcher et al., 1995; Tataranni et al., 1999: Liotti et al., 2000; Smith et al., 2002a, b).”
Lyketsos, C. G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C. D., Munro, C., Baker, A. S., Sheppard, J.-M. E., Frangakis, C., Brandt, J., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.737 · Cited by 398 · cited 1×
“SSRIs have been shown to be effective in treating depression secondary to Alzheimer's disease, which may also improve function (Lyketsos et al., 2003).”
Garcia-Alloza, M., Gil-Bea, F. J., Diez-Ariza, M., Chen, C. P. L.-H., Francis, P. T., Lasheras, B., & Ramirez, M. J. (2005) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2004.06.007 · Cited by 244 · cited 1×
“…postmortem neurochemical measures have been associated with cognitive impairment, rate of cognitive decline and behavioural symptoms in Alzheimer's disease, indicating that dysfunction of both systems is related to greater symptomatology (Palmer et al., 1988; Garcia-Alloza et al., 2005).”
Smith, G. S. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530350056020 · Cited by 178 · cited 2×
“In addition, a glutamatergic mechanism may be involved in the cerebral metabolic deficits observed in Alzheimer’s disease (Smith et al., 1992).”
Self-citationNELSON, R., GUO, Z., HALAGAPPA, V, PEARSON, M., GRAY, A., MATSUOKA, Y., BROWN, M., MARTIN, B., IYUN, T., & MAUDSLEY, S. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.01.037 · Cited by 173 · cited 1×
“…effect of SSRI's, as well as recent evidence of a prophylactic effect of SSRI's in animal models of Alzheimer's disease had led to the suggestion that chronic use of the SSRI in neurodegenerative disease may improve function and slow disease progression (Duman, 1998, Nelson et al., 2007).”
Cited by
A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease
Laxton, A. W., Tang‐Wai, D. F., McAndrews, M. P., Zumsteg, D., Wennberg, R., Keren, R., Wherrett, J., Naglie, G., Hamani, C., Smith, G. S., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22089 · Cited by 812
Self-citationCooper, C., Sommerlad, A., Lyketsos, C. G., & Livingston, G. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14070878 · Cited by 570
The use of PET in Alzheimer disease
Nordberg, A., Rinne, J. O., Kadir, A., & Långström, B. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.217 · Cited by 449
Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.001 · Cited by 378
“[53] Smith GS, Kramer E, Ma Y, Hermann CR, Dhawan V, Chaly T, et al.”
Self-citationThe serotonergic system in ageing and Alzheimer's disease
Rodríguez, J. J., Noristani, H. N., & Verkhratsky, A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.010 · Cited by 264
Metadata
- Authors
- Smith, G. S., Kramer, E., Ma, Y., Hermann, C. R., Dhawan, V., Chaly, T., & Eidelberg, D.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-02
- Volume
- 132
- Issue
- 2
- Pages
- 392-401
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1983127199
- Cited by
- 38
- References
- 11
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. https://app.cochat.ai/papers/10.1093/brain/awn326
- The paper
- Smith, G. S., Kramer, E., Ma, Y., Hermann, C. R., Dhawan, V., Chaly, T., & Eidelberg, D. (2009). Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. https://doi.org/10.1093/brain/awn326
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.